June 13, 2013 Approval Letter - HPC Cord Blood BLA 125432
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
Our STN: BL 125432/0
LifeSouth Community Blood Centers, Inc.
Attention: Ms. Nancy Eckert
4039 Newberry Road
Gainesville, FL 32607
Dear Ms. Eckert:
We have approved your biologics license application for HPC, Cord Blood effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, HPC, Cord Blood, manufactured from the date of this authorization forward, under your existing Department of Health and Human Services U.S. License No. 1647. HPC, Cord Blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
Under this authorization, you are approved to manufacture HPC, Cord Blood at your facility in Gainesville, Florida. You must label your product with the proper name HPC, Cord Blood and will market it in 25 mL cryobags.
We did not refer your application to the Cellular, Tissue, and Gene Therapy Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues which would have benefited from an advisory committee discussion.
The dating period for HPC, Cord Blood shall be 11 months from the date of manufacture when stored at ≤ -150° C. The date of manufacture shall be defined as the date the product is cryopreserved. We have approved the stability protocol in your license application for the purpose of extending the expiration dating period of HPC, Cord Blood under 21 CFR 601.12.
You currently are not required to submit samples of future lots of HPC, Cord Blood to the Center for Biologics Evaluation and Research (CBER) for release by the Director, CBER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1 requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.
You must submit information to your biologics license application for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of HPC, Cord Blood, or in the manufacturing facilities.
You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA-3486 to the Director, Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, HFM-600, 1401 Rockville Pike, Rockville, MD 20852-1448.
Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. In addition, please submit three original paper copies for carton and container final printed labeling. All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.
You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).
ADVERSE EVENT REPORTING
You must submit adverse experience reports in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80) and you must submit distribution reports as described in 21 CFR 600.81. You should submit postmarketing adverse experience reports and distribution reports to the Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology HFM-210, Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448. Prominently identify all adverse experience reports as described in 21 CFR 600.80. Per 21 CFR 600.2(f), please refer to http://www.fda.gov/AboutFDA/CentersOffices/CBER/ucm106001.htm
for updated mailing address information.
In addition, you must submit adverse event reports for any infectious disease transmission within 15 days after learning of the event. Infectious disease transmission refers to an adverse event that involves suspected or confirmed transmission of an infectious agent, whether the recipient develops the infectious disease or only has serologic or other evidence.
FDA regulations require Quarterly Periodic Adverse Experience Reports (PAERS) to contain a narrative summary and analysis of the information in the report and an analysis of the 15-day Alert reports submitted during the reporting interval (21 CFR 600.80(c)2). The narrative summary in PAERs for HPC, Cord Blood should include a detailed summary and assessment of all serious infusion reactions observed during the reporting period, as well as your assessment of each case and the overall frequency of serious infusion reactions since approval and during the reporting period. PAERs should also include any adverse event (e.g., infusion reaction or other adverse event) information forwarded to you from the Stem Cell Therapeutics Outcomes Database (SCTOD) during the reporting period. PAERs should also include the number of units released for infusion and the number of patients receiving infusions with HPC, Cord Blood during the reporting period.
In addition, we acknowledge receipt of your February 7, 2013 letter in which you agreed to the following:
1. You will implement a safety outcomes monitoring and analysis plan. This plan will include a) maintenance of an observational database to include, for all HPC, Cord Blood units released, information including but not limited to, time to neutrophil recovery, graft failure, survival, cause of death, infusion reactions, and other adverse experiences, and b) aggregate analyses of interval and cumulative adverse experience reports, and c) safety outcomes analyses of interval and cumulative data that address early mortality, graft failure-related mortality, graft failure, time to neutrophil recovery, infusion-related events, and other adverse experiences. Reports will include a description of the population analyzed, results of the analyses, whether outcomes indicators were triggered and, if so, what actions were implemented as a result.
2. You will submit a 15-day “alert report” for each serious infusion reaction associated with administration of HPC, Cord Blood.
If you have any questions, please contact the Regulatory Project Manager, Candace Jarvis, at
Celia M. Witten, Ph.D., M.D.
Office of Cellular, Tissue, and Gene Therapies
Center for Biologics Evaluation and Research